Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Ifosfamide in the treatment of bladder cancer
B. J. Roth
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
14
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ifosfamide in the treatment of bladder cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ifosfamide
100%
Bladder Cancer
100%
Response Rate
28%
Paclitaxel
28%
Phase II Trial
28%
Cisplatin
28%
Advanced Bladder Cancer
28%
Histology
14%
Dose-limiting Toxicity
14%
Chemotherapy
14%
Patient Demographics
14%
Occult
14%
Previously Untreated Patients
14%
Prior Chemotherapy
14%
Renal Insufficiency
14%
Chemotherapy Regimen
14%
Central Nervous System Toxicity
14%
Objective Response
14%
Myelosuppression
14%
Gallium Nitride
14%
Vinblastine
14%
Combination Regimen
14%
Nephrotoxicity
14%
Ontology
14%
Medicine and Dentistry
Ifosfamide
100%
Bladder Cancer
100%
Paclitaxel
28%
Cisplatin
28%
Phase II Trials
28%
Chemotherapy
28%
Patient Population
14%
Patient History of Chemotherapy
14%
Renal Failure
14%
Bone Marrow Suppression
14%
Nephrotoxicity
14%
Vinblastine
14%
Gallium Nitrate
14%
Central Nervous System Toxicity
14%
Diseases
14%
Histology
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ifosfamide
100%
Bladder Cancer
100%
Paclitaxel
28%
Cisplatin
28%
Phase II Trials
28%
Chemotherapy Regimens
28%
Kidney Failure
14%
Patient History of Chemotherapy
14%
Central Nervous System Toxicity
14%
Bone Marrow Suppression
14%
Nephrotoxicity
14%
Vinblastine
14%
Gallium Nitrate
14%
Diseases
14%